CaroGen Corporation develops investigational RNA-based immunotherapies for infectious diseases.
CaroGen Corporation develops investigational immunotherapies using its AVIDIO virus-like vesicle platform. Its lead candidate, CARG-201, is intended for people with chronic hepatitis B.
CaroGen retains infectious-disease rights and has licensed oncology applications of AVIDIO to Viridion Therapeutics. The company reports grant funding for its development work.
Loading profile details…
Biotech Research · Business involvement
As of 2026-11-08
Loading recent changes…
Editorial profile by MoneyMakers. Sources reviewed .
Brand marks identify the organization. Logo from the official website.
Co-founder
Co-founder, CEO and chairman of CaroGen Corporation.
View personal profile